公开(公告)号：WO1996031219A1

公开(公告)日：1996-10-10

申请号：PCT/US1996004665

申请日：1996-04-04

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  GARLEB, Keith, Allen ,  WOLF, Brian, Warren ,  MEULBROEK, Jonathan, Allan ,  WHEELER, Keith, Brian ,  CAMPBELL, Shelia, Martinson ,  WALTON, Joseph, Edward

IPC: A61K31/70

CPC classification number: A61K31/7016 ,  A61K31/702 ,  A61K33/14 ,  A61K33/00 ,  A61K31/70 ,  A61K2300/00

Abstract: The primary etiology of antibiotic-associated diarrhea (also known as pseudomembranous colitis) has been recognized as Clostridium difficile. It is believed that the indigenous microflora of a healthy individual suppresses the normally present C. difficile. However, when the indigenous microflora are disrupted (e.g., during antibiotic treatment) overgrowth of C. difficile may occur causing diarrhea and colitis. Treatment of C. difficile with antibiotics has proven effective, but many times relapse occurs; and dehydration due to diarrhea is an exacerbating problem. It has been suggested that normalization of the microflora will inhibit C. difficile relapse. Indigestible oligosaccharides have been shown to inhibit C. difficile infection. An oral rehydration solution containing such indigestible oligosaccharides also provides fluid and electrolyte replacement.

Abstract translation: 抗生素相关性腹泻（也称为假膜性结肠炎）的主要病因已经被认为是艰难梭菌。 据信，健康个体的土着微生物群落抑制了正常存在的艰难梭菌。 然而，当土着微生物群落被破坏时（例如，在抗生素治疗期间），可能发生艰难梭菌的过度生长，导致腹泻和结肠炎。 用抗生素治疗艰难梭菌已被证明是有效的，但多次发生复发; 而由于腹泻引起的脱水是一个加剧的问题。 有人认为微生物群落的正常化会抑制艰难梭菌的复发。 已经显示难消化的寡糖抑制艰难梭菌感染。 包含这种难消化的寡糖的口服补液溶液也提供流体和电解质替代物。

公开(公告)号：WO1995026646A1

公开(公告)日：1995-10-12

申请号：PCT/US1995002657

申请日：1995-03-06

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  DEMICHELE, Stephen, Joseph ,  GARLEB, Keith, Allen ,  McEWEN, John, William ,  FULLER, Martha, Kay

IPC: A23L01/30

CPC classification number: A23L33/12 ,  A23L33/40

Abstract: An enteral nutritional product and method of treatment for a person having ulcerative colitis contains in combination (a) an oil blend which contains eicosapentaenoic acid (20:5n3) and/or docosahexaenoic acid (22:6n3), and (b) a source of indigestible carbohydrate which is metabolized to short chain fatty acids by microorganisms present in the human colon. Preferably the nutritional product also contains one or more nutrients which act as antioxidants.

Abstract translation: 具有溃疡性结肠炎的肠内营养产品和治疗方法组合（a）含有二十碳五烯酸（20:5n3）和/或二十二碳六烯酸（22：6n3）的油混合物和（b） 难以消化的碳水化合物，其通过存在于人结肠中的微生物代谢成短链脂肪酸。 优选地，营养产品还含有一种或多种作为抗氧化剂的营养物质。

公开(公告)号：WO1997022352A1

公开(公告)日：1997-06-26

申请号：PCT/US1996020347

申请日：1996-12-20

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  GARLEB, Keith, Allen ,  WOLF, Bryan, Allen

IPC: A61K35/74

CPC classification number: A61K35/747 ,  A23L29/065 ,  A23Y2220/03 ,  Y02A50/488 ,  Y10S435/853 ,  Y10S435/854

Abstract: Cryptosporidium parvum (the cause of cryptosporidiosis) has become one of the most common enteropathogens causing diarrhea worldwide. Symptoms associated with cryptosporidiosis are very debilitating especially in the immunocompromised subject (e.g., AIDS patient). Clinical features include severe, chronic diarrhea, abdominal cramps, fatigue, weight loss, etc. which lead to increased health care costs and increased mortality. There is described herein a method of inhibiting the severity of Cryptosporidium parvum infection by enterally administering a therapeutically effective amount of Lactobacillus acidophilus.

Abstract translation: 隐孢子虫隐孢子虫（隐孢子虫病的原因）已经成为全世界引起腹泻的最常见的肠道病原体之一。 与隐孢子虫病有关的症状特别是在免疫受损的受试者（例如艾滋病患者）中非常虚弱。 临床特征包括严重的慢性腹泻，腹部痉挛，疲劳，体重减轻等，导致医疗费用增加和死亡率增加。 本文描述了通过肠内施用治疗有效量的嗜酸乳杆菌来抑制隐孢子虫感染的严重性的方法。

公开(公告)号：WO1993000019A1

公开(公告)日：1993-01-07

申请号：PCT/US1992003801

申请日：1992-05-07

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  BEHR, Stephen, Richard ,  CRAIG, Lisa, Diane ,  GARLEB, Keith, Allen ,  NEAL, Cynthia, Sue ,  CHMURA, James, Norman ,  ANLOAGUE, Paul Separa ,  CUNNINGHAM, Mary, Beth ,  SERTL, David, Charles

IPC: A23L02/38

CPC classification number: A23L33/22 ,  A23L7/115 ,  A23L29/25 ,  A23L29/262 ,  A23L33/12 ,  A23L33/21 ,  A23L33/40 ,  Y10S426/804 ,  Y10S514/951 ,  Y10S514/965

Abstract: A liquid nutritional product comprising a fat source and a dietary fiber system. The dietary fiber system as a whole comprises by weight: a) 5 % to 50 % dietary fiber which is both soluble and fermentable, 5 % to 20 % dietary fiber which is both soluble and non-fermentable, and 45 % to 80 % dietary fiber which is both insoluble and non-fermentable. Less than 10 % of the total calories in the product comprise saturated fatty acids, no more than 10 % of the total calories in the product comprises polyunsaturated fatty acids, and the ratio of the n-6 to n-3 fatty acids in the product being in the range of 2 to 10. Preferably the dietary fiber which is both soluble and fermentable is gum arabic; the fiber which is both soluble and non-fermentable is sodium carboxymethylcellulose, and the fiber which is both insoluble and non-fermentable is oat hull fiber.

公开(公告)号：WO1997022353A1

公开(公告)日：1997-06-26

申请号：PCT/US1996020348

申请日：1996-12-20

Applicant: ABBOTT LABORATORIES ,  BIOGAIA BIOLOGICS AB

Inventor： ABBOTT LABORATORIES ,  BIOGAIA BIOLOGICS AB ,  GARLEB, Keith, Allen ,  WOLF, Bryan, Allen ,  CASAS, Ivan, A.

IPC: A61K35/74

CPC classification number: A61K35/747 ,  A23L29/065 ,  A23Y2220/71 ,  Y02A50/488

Abstract: Cryptosporidium parvum (the cause of cryptosporidiosis) has become one of the most common enteropathogens causing diarrhea worldwide. Symptoms associated with cryptosporidiosis are very debilitating especially in the immunocompromised subject (e.g., AIDS patient). Clinical features include severe, chronic diarrhea, abdominal cramps, fatigue, weight loss, etc. which lead to increased health care costs and increased mortality. There is disclosed herein a method of inhibiting the severity of Cryptosporidium parvum infection by enterally administering a therapeutically effective amount of Lactobacillus reuteri.

Abstract translation: 隐孢子虫隐孢子虫（隐孢子虫病的原因）已经成为全世界引起腹泻的最常见的肠道病原体之一。 与隐孢子虫病有关的症状特别是在免疫受损的受试者（例如艾滋病患者）中非常虚弱。 临床特征包括严重的慢性腹泻，腹部痉挛，疲劳，体重减轻等，导致医疗费用增加和死亡率增加。 本文公开了一种通过肠内施用治疗有效量的罗伊氏乳杆菌抑制隐孢子虫感染严重性的方法。

公开(公告)号：WO1996028983A1

公开(公告)日：1996-09-26

申请号：PCT/US1996003754

申请日：1996-03-21

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  BEHR, Stephen, Richard ,  SEEDS, Jeffrey, Keith ,  LAMB, Catherine, Sue ,  GARLEB, Keith, Allen ,  WALTON, Joseph, Edward

IPC: A23P01/04

CPC classification number: A61K9/0056 ,  A23L7/122 ,  A23L7/126 ,  A23L29/238 ,  A23L33/21 ,  A23P10/30 ,  Y10S514/824

Abstract: A nutritional product having a solid matrix containing protein, fat and carbohydrate has disposed therein particles of dietary fiber encapsulated in zein. The preferred dietary fiber is guar. Such a nutritional product may be used for reducing the serum cholesterol in a mammal.

Abstract translation: 具有含有蛋白质，脂肪和碳水化合物的固体基质的营养产品在其中包含包封在玉米蛋白中的膳食纤维颗粒。 优选的膳食纤维是瓜尔胶。 这样的营养产品可用于降低哺乳动物的血清胆固醇。

公开(公告)号：WO1994002166A1

公开(公告)日：1994-02-03

申请号：PCT/US1993006005

申请日：1993-06-23

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  GARLEB, Keith, Allen ,  DEMICHELE, Stephen, Joseph ,  RAUSCH, Linda, Sue ,  FULLER, Martha, Kay ,  BEHR, Stephen, Richard

IPC: A61K37/02

CPC classification number: A61K36/48 ,  A23L33/12 ,  A23L33/40 ,  A61K36/02 ,  A61K36/28 ,  A61K36/286 ,  A61K36/30 ,  A61K36/31 ,  A61K36/899 ,  A61K38/01 ,  Y10S426/80 ,  A61K2300/00

Abstract: An enteral nutritional product for a person having a neurological injury is very low in carbohydrate, but high in fat. The fat is supplied by a lipid blend having a ratio of n-6 to n-3 fatty acids in the range of 1 to 6. Preferably the nutritional product contains nutrients having antioxidant properties, for example beta-carotene, vitamin E, vitamin C, taurine, molybdenum and selenium.

Abstract translation: 具有神经损伤的人的肠内营养产品碳水化合物非常低，但脂肪含量高。 脂肪由具有1至6范围内的n-6至n-3脂肪酸的比例的脂质混合物提供。优选地，营养产品含有具有抗氧化性质的营养物质，例如β-胡萝卜素，维生素E，维生素C ，牛磺酸，钼和硒。

公开(公告)号：WO1993000020A1

公开(公告)日：1993-01-07

申请号：PCT/US1992003901

申请日：1992-05-07

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  GARLEB, Keith, Allen ,  CHMURA, James, Norman ,  ANLOAGUE, Paul, Separa ,  CUNNINGHAM, Mary, Beth ,  SERTL, David, Charles

IPC: A23L02/38

CPC classification number: A23L33/22 ,  A23L9/10 ,  A23L33/115 ,  A23L33/21 ,  Y10S426/804 ,  Y10S514/951 ,  Y10S514/965

Abstract: Taken as a whole a blend of dietary fiber contains, by weight: 5 % to 50 % of a dietary fiber which is both soluble and fermentable; 5 % to 20 % of a dietary fiber which is both soluble and non-fermentable; and 45 % to 80 % of a dietary fiber which is both insoluble and non-fermentable. Preferably, the dietary fiber which is both soluble and fermentable is gum arabic; the dietary fiber which is both soluble and non-fermentable is sodium carboxymethylcellulose; and the dietary fiber which is both insoluble and non-fermentable is oat hull fiber.

公开(公告)号：EP0814675B1

公开(公告)日：2003-05-28

申请号：EP96908867.3

申请日：1996-03-21

Applicant: Abbott Laboratories

Inventor： BEHR, Stephen, Richard ,  SEEDS, Jeffrey, Keith ,  LAMB, Catherine, Sue ,  GARLEB, Keith, Allen ,  WALTON, Joseph, Edward

IPC: A23P1/04 ,  A23L1/0526 ,  A61K9/50

CPC classification number: A61K9/0056 ,  A23L7/122 ,  A23L7/126 ,  A23L29/238 ,  A23L33/21 ,  A23P10/30 ,  Y10S514/824

Abstract: A nutritional product having a solid matrix containing protein, fat and carbohydrate has disposed therein particles of dietary fiber encapsulated in zein. The preferred dietary fiber is guar. Such a nutritional product may be used for reducing the serum cholesterol in a mammal.

公开(公告)号：EP0814822A1

公开(公告)日：1998-01-07

申请号：EP96943821.0

申请日：1996-12-20

Applicant: Abbott Laboratories ,  BIOGAIA BIOLOGICS AB

Inventor： GARLEB, Keith, Allen ,  WOLF, Bryan, Allen ,  CASAS, Ivan, A.

IPC: A23L1 ,  A61K35

CPC classification number: A61K35/747 ,  A23L29/065 ,  A23Y2220/71 ,  Y02A50/488

Abstract: Cryptosporidium parvum (the cause of cryptosporidiosis) has become one of the most common enteropathogens causing diarrhea worldwide. Symptoms associated with cryptosporidiosis are very debilitating especially in the immunocompromised subject (e.g., AIDS patient). Clinical features include severe, chronic diarrhea, abdominal cramps, fatigue, weight loss, etc. which lead to increased health care costs and increased mortality. There is disclosed herein a method of inhibiting the severity of Cryptosporidium parvum infection by enterally administering a therapeutically effective amount of Lactobacillus reuteri.